• Sino Biopharmaceutical’s Chia Tai Tianqing won China CDE acceptance of an NDA for TQB3909, a BCL-2 inhibitor tablet.
• Filing targets adult relapsed or refractory CLL/SLL patients previously treated with at least one systemic therapy, including a BTK inhibitor.
• CDE granted priority review status in July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260804-12270862), on August 04, 2026, and is solely responsible for the information contained therein.